Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Company Overview - Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers [3] - The company is working on PYX-201, an antibody-drug conjugate (ADC) targeting EDB+FN, which is currently in Phase 1 clinical studies for various solid tumors [3] Upcoming Events - Lara S. Sullivan, M.D., President and CEO of Pyxis Oncology, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2025, at 2:20 PM EST [1] - A live webcast and replay of the fireside chat will be available on the company's Investor Relations website [2]